natgillin/translations-raw huggingface dataset:
A single dose of albiglutide 50 mg did not impair the glucagon, epinephrine, norepinephrine, cortisol or growth hormone counter-regulatory hormone response to hypoglycaemia. 
Posamezen odmerek 50 mg albiglutida ni okrnil protiregulacijskega hormonskega odziva glukagona, adrenalina, noradrenalina, kortizola ali rastnega hormona na hipoglikemijo.
If you think this applies to you, don't use Eperzan until you have checked with your doctor, nurse or pharmacist. 
Če menite, da to velja za vas, ne uporabite zdravila Eperzan, dokler se ne posvetujete z zdravnikom, medicinsko sestro ali farmacevtom.
Fertility For both men and women, it is not known if Eperzan could affect your fertility. 
Ne za moške ne za ženske ni znano, ali zdravilo Eperzan lahko vpliva na plodnost.
• heartburn (gastro-oesophageal reflux) 
• zgaga (gastroezofagealni refluks).
After reconstitution, continue to follow the steps in the instructions for use to attach the needle, prime the pen injector and administer the injection. 
Po pripravi nadaljujte s koraki v navodilih za uporabo, da boste namestili iglo, pripravili peresnik in injicirali zdravilo.
Albiglutide also produced dose-dependent increases in serum calcitonin levels in a 21-day study in mice, suggesting that thyroid tumours in rodents are a theoretical possibility for albiglutide as well. 
Tudi albiglutid je v 21-dnevni študiji pri miših povzročil od odmerka odvisno zvišanje koncentracije kalcitonina v serumu; to kaže, da so ščitnični tumorji pri glodalcih teoretična možnost tudi z albiglutidom.
Treatment with Eperzan alone or in combination with one or two oral antidiabetic medicinal products resulted in a reduction in fasting plasma glucose from baseline as compared to placebo of 1.3 to 2.4 mmol/l. 
Zdravljenje z zdravilom Eperzan samim ali v kombinaciji z enim ali dvema peroralnima antidiabetičnima zdraviloma je znižalo glukozo v plazmi na tešče od izhodišča za 1,3 do 2,4 mmol/l v primerjavi s placebom.
Store pens and needles in the original carton until use. 
Peresnike in igle do uporabe shranjujte v originalni ovojnini.
Anticipated symptoms of an overdose may be severe nausea, vomiting or headache. 
Pričakovani simptomi prevelikega odmerjanja so huda navzea, bruhanje in glavobol.
Allergic reactions 
Alergijska reakcija
Albiglutide is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes. 
Albiglutid je beljakovina in pričakovana pot njegove presnove je razgradnja v majhne peptide in posamezne aminokisline s široko razprostranjenimi proteolitičnimi encimi.
• When initiating treatment with albiglutide, you may experience fluid loss from vomiting, nausea, diarrhoea or dehydration. 
• ob začetku zdravljenja z albiglutidom lahko pride do izgube tekočine zaradi bruhanja, slabosti, driske ali dehidracije.
Change at Week 104 b 
Sprememba po 104 tednihb
The risk of hypoglycaemia is increased when Eperzan is used in combination with insulin secretagogues (such as sulphonylurea) or with insulin. 
Tveganje za hipoglikemijo se poveča, če se zdravilo Eperzan uporabi v kombinaciji z insulinskimi sekretagogi (kot so sulfonilsečnine) ali z insulinom.
Eperzan has not been studied in combination with prandial insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium/glucose cotransporter 2 (SGLT2) inhibitors. 
Zdravilo Eperzan ni raziskano v kombinaciji s prandialnim insulinom, zaviralci dipeptidilpeptidaze-4 (DPP-4) ali zaviralci soprenašalca natrija/glukoze 2 (SGLT2).
What Eperzan looks like and contents of the pack 
Izgled zdravila Eperzan in vsebina pakiranja
IMPORTANT: Make sure you do not twist the pen to [3] until you have attached the needle in step 5. 
POMEMBNO: Poskrbite, da ne boste zasukali peresnika na [3], dokler v 5. koraku ne namestite igle.
None of these antibodies were shown to neutralise the activity of albiglutide in an in vitro assay and antibody formation was generally transient and was not associated with reduced efficacy (HbA1c and FPG). 
Nobeno od protiteles ni nevtraliziralo delovanja albiglutida v preizkusu in vitro; nastajanje protiteles je bilo na splošno prehodno in ga ni spremljala manjša učinkovitost (HbA1c in glukoza v plazmi na tešče).
Albiglutide delays gastric emptying, and has the potential to impact the absorption of concomitantly administered oral medicinal products. 
Albiglutid upočasni praznjenje želodca in tako lahko vpliva na absorpcijo sočasno peroralno uporabljenih zdravil.
After discontinuation, the effect of Eperzan may continue as plasma levels of albiglutide decline slowly over about 3 to 4 weeks. 
Prenehanje zdravljenja Po prenehanju uporabe lahko učinek zdravila Eperzan traja še približno 3 do 4 tedne, ker se koncentracija albiglutida v plazmi znižuje počasi.
The durability of glycaemic control for Eperzan over time relative to other classes of type 2 antidiabetic agents and placebo is shown in Figure 1 as add-on to metformin. 
Trajnost urejenosti glikemije z zdravilom Eperzan po času glede na druge skupine antidiabetičnih zdravil za tip 2 in glede na placebo prikazuje slika 1 kot dodatek metforminu.
Pancreatitis, intestinal obstruction 
pankreatitis, obstrukcija prebavil
However, when used in combination with a sulphonylurea or a basal insulin, blood glucose self-monitoring may become necessary to adjust the dose of the sulphonylurea or the basal insulin. 
Če pa se to zdravilo uporablja v kombinaciji s sulfonilsečnino ali bazalnim insulinom, lahko postane samomerjenje glukoze v krvi potrebno za prilagoditev odmerka sulfonilsečnine ali bazalnega insulina.
The mean apparent clearance of albiglutide is 67 ml/h with an elimination half-life of approximately 5 days based on estimations from the population PK analyses from phase III patient studies and measured values. 
Povprečni navidezni očistek albiglutida je 67 ml/uro in eliminacijski razpolovni čas je približno 5 dni; vrednosti temeljita na ocenah populacijskih farmakokinetičnih analiz iz študij III. faze pri bolnikih in na izmerjenih vrednostih.
Caution is advised if used concomitantly with albiglutide (see section 4.8). 
V primeru sočasne uporabe z albiglutidom je potrebna previdnost (glejte poglavje 4.8).
If you forget to use Eperzan 
Če ste pozabili uporabiti zdravilo Eperzan
• low blood sugar (hypoglycaemia) if you use Eperzan on its own or in combination with metformin or pioglitazone 
• nizek krvni sladkor (hipoglikemija), če zdravilo Eperzan uporabljate v kombinaciji z metforminom ali pioglitazonom,
• Use the pen immediately after you have attached and primed the needle otherwise the solution can dry up inside the needle and block it. 
• Peresnik uporabite takoj zatem, ko ste nanj namestili iglo in jo pripravili za uporabo, sicer se lahko raztopina v igli posuši in zamaši iglo.
INFORMATION IN BRAILLE eperzan 30 
PODATKI V BRAILLOVI PISAVI eperzan 30
There is limited experience of albiglutide when combined with thiazolidinediones alone, sulphonylureas + thiazolidinediones, and metformin + sulphonylureas + thiazolidinediones. 
Malo je izkušenj z albiglutidom v kombinaciji s samimi tiazolidindioni, sulfonilsečninami + tiazolidindioni in metforminom + sulfonilsečninami + tiazolidindioni.
Severe hypoglycaemia requiring the assistance of another person for treatment occurred uncommonly: 0.3% among patients receiving Eperzan and 0.4% among patients receiving a comparator. 
Hude hipoglikemije, ki so za zdravljenje zahtevale posredovanje druge osebe, so bile občasne: 0,3 % med prejemniki zdravila Eperzan in 0,4 % med prejemniki primerjalnih zdravil.
After reconstitution, the pen should be used within 8 hours. 
Po pripravi je treba peresnik uporabiti v 8 urah.
Do not dispose of the used pen in the household waste. 
Porabljenega peresnika ne odvrzite med gospodinjske odpadke.
Studies in mice showed reduced oestrous cycling at maternally toxic doses, but did not indicate harmful effects with respect to fertility (see section 5.3). 
Študije na miših so v odmerkih, toksičnih za samice-matere, pokazale zmanjšanje estrusnih ciklusov, niso pa pokazale škodljivih učinkov na plodnost (glejte poglavje 5.3).
Use of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. 
Akutni pankreatitis Uporaba agonistov receptorjev GLP-1 je bila povezana s tveganjem za pojav akutnega pankreatitisa.
Steady-state exposures are achieved following 3-5 weeks of once-weekly administration. 
Izpostavljenost v stanju dinamičnega ravnovesja je dosežena po 3 do 5 tednih uporabe enkrat na teden.
A needle is provided with each pen. 
Vsakemu peresniku je priložena igla.
DO NOT use if the pen is expired or shows the incorrect dose. 
NE UPORABITE peresnika, če se je rok uporabnosti že iztekel, ali če kaže nepravilen odmerek.
DO NOT attach the needle before Step 5. 
NE NAMESTITE igle pred 5. korakom.
When using Eperzan with insulin, each medicinal product must be administered as a separate injection. 
Če bolnik zdravilo Eperzan uporablja z insulinom, je treba zdravili injicirati ločeno.
If it is more than 3 days after the missed dose, patients should wait and administer their next regularly scheduled weekly dose. 
Če so od izpuščenega odmerka pretekli že več kot 3 dnevi, mora bolnik počakati in uporabiti naslednji odmerek ob rednem času zanj.
• because your body does not make enough insulin to control the level of sugar in your blood or 
• ker vam v telesu ne nastaja dovolj insulina, da bi uravnal koncentracijo krvnega sladkorja
There is no information about the safety of Eperzan in pregnant women. 
O varnosti zdravila Eperzan pri nosečnicah ni podatkov.
Hold the pen upright before attaching the needle. 
Držite peresnik pokonci, preden namestite iglo.
What you need to know before you use Eperzan 
Kaj morate vedeti, preden boste uporabili zdravilo Eperzan
Step 3 Wait 30 minutes 
3. korak Počakajte 30 minut
Follow instructions to twist the cartridge until ‘2' appears in the number window and a “click” is heard. 
Sledite navodilom in zasučite vložek, dokler se v številskem okencu ne pojavi "2" in zaslišite klik.
There are no data on the effects of Eperzan on human fertility. 
Podatkov o vplivu zdravila Eperzan na plodnost pri človeku ni.
Step 3 Wait 15 minutes 
3. korak Počakajte 15 minut
DO NOT use the pen if the injection button does not pop out. 
NE UPORABITE peresnika, dokler gumb za injiciranje ne pogleda ven.
If you do not hear a “click” when the [2] or when the [3] is moved into the number window, you may not have the number fully centered in the window. 
Če ne zaslišite "klik", ko se v številčno okence pomakneta [2] ali [3], številki morda nista povsem v sredini okenca.
The rate of symptomatic hypoglycaemia was higher for Eperzan when used in combination with a sulphonylurea (15% to 22%) or with insulin (18%) compared to combinations not including a sulphonylurea or insulin (1% to 4%). 
Delež simptomatskih hipoglikemij je bil večji, če se je zdravilo Eperzan uporabilo v kombinaciji s sulfonilsečnino (od 15 do 22 %) ali insulinom (18 %), kot če se je uporabljalo v kombinacijah, ki niso vključevale sulfonilsečnine ali insulina (od 1 do 4 %).
As albiglutide is an albumin fusion molecule, plasma protein binding has not been assessed. 
Ker je albiglutid albuminska fuzijska molekula, vezave na beljakovine v plazmi niso ocenili.
After this time, pens should be used or thrown away. 
Po tem času morate peresnike uporabiti ali zavreči.
There are no adequate data to support the use of Eperzan during breast-feeding in humans. 
Ni ustreznih podatkov, ki bi podpirali uporabo zdravila Eperzan med obdobjem dojenja pri človeku.
Injection site reactions (typically including rash, erythema, or itching at the injection site) occurred in 15% of patients treated with Eperzan compared to 7% with all comparators and led to discontinuation in 2% of all patients treated with Eperzan. 
Reakcije na mestu injiciranja (po navadi z izpuščajem, rdečino ali srbenjem na mestu injiciranja) so se pojavile pri 15 % bolnikov, zdravljenih z zdravilom Eperzan, in pri 7 % bolnikov, zdravljenih z vsemi primerjalnimi zdravili; te reakcije so povzročile prekinitev zdravljenja pri 2 % vseh bolnikov, zdravljenih z zdravilom Eperzan.
Durability of glycaemic control 
Trajnost urejenosti glikemije
Inspect the pen to ensure that the number ‘1' is visible in the number window. 
Preglejte peresnik in se prepričajte, da je v številčnem okencu vidna številka "1".
Adverse reactions reported from a pooled analysis of seven placebo- and active-controlled phase III studies over the entire treatment period are presented in Table 1. 
Neželeni učinki, zabeleženi v kumulativni analizi sedmih študij III. faze, kontroliranih s placebom ali zdravilno učinkovino med celotnim obdobjem zdravljenja, so prikazani v preglednici 1.
INFORMATION IN BRAILLE eperzan 50 
PODATKI V BRAILLOVI PISAVI eperzan 50
Avoid shaking as this can result in foaming. 
Ne stresajte, ker to lahko povzroči penjenje.
You can use your abdomen, thigh, or upper arm. 
Lahko uporabite trebuh, stegno ali nadlaket.
Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. 
Uporaba agonistov receptorjev GLP-1 je lahko povezana z neželenimi učinki na prebavilih.
If you have attached the needle, EPERZAN should be used right away. 
Če ste že namestili iglo, morate zdravilo EPERZAN uporabiti takoj.
• rash, redness or itching of the skin where you have injected Eperzan 
• izpuščaj, rdečina ali srbenje kože na mestu, kjer ste injicirali zdravilo Eperzan.
Eperzan may be administered at any time of day without regard to meals. 
Zdravilo Eperzan se lahko uporabi kadar koli tekom dneva in ne glede na obroke.
Throw away the pen if frozen. 
Če peresnik zmrzne, ga zavrzite.
The warning signs of low blood sugar may include cold sweat, cool pale skin, headache, feeling drowsy, weakness, dizziness, feeling confused or irritable, feeling hungry, fast heart beat and feeling jittery. 
• nizek krvni sladkor (hipoglikemija), če zdravilo Eperzan uporabljate v kombinaciji z insulinom ali sulfonilsečnino; med opozorilnimi znaki nizkega krvnega sladkorja so lahko mrzel pot, hladna bleda koža, glavobol, zaspanost, šibkost, omotičnost, zmedenost ali razdražljivost, občutek lakote, hitro bitje srca in občutek tresenja.
The incidence rates observed for first MACE+ were 1.2 and 1.1 events per 100 person-years for Eperzan versus all comparators, respectively. 
Stopnja incidence za prvi MACE+ je bila pri zdravilu Eperzan 1,2 in pri vseh primerjalnih zdravilih 1,1 dogodka na 100 bolnik-let.
Patients were randomised (1:1:1) to Eperzan 30 mg once weekly, Eperzan 30 mg once weekly uptitrated to 50 mg once weekly at week 12, or placebo. 
Bolniki so bili randomizirani (1:1:1) na zdravilo Eperzan 30 mg enkrat na teden, zdravilo Eperzan 30 mg enkrat na teden z zviševanjem na 50 mg enkrat na teden 12. teden ali na placebo.
It is not known if Eperzan passes into your breast milk. 
Eperzan prehaja v materino mleko.
• chest infection (pneumonia) 
• okužba v prsnem košu (pljučnica),
6b Hold pen upright, slowly twist the clear cartridge several times in the direction of the arrow until you feel/hear the pen “click” and you see the [3] in the number window (Figure O). 
6b Peresnik držite pokonci in prozorni vložek počasi večkrat zasučite v smeri puščice, dokler ne začutite ali zaslišite, da peresnik "klikne" in v številčnem okencu vidite [3] (Slika O).
Eperzan demonstrated glycaemic lowering and was statistically superior in reduction in HbA1c from baseline compared to placebo, sitagliptin, or glimepiride (see Table 3). 
Zdravilo Eperzan je znižalo glikemijo in je bilo statistično značilno superiorno pri znižanju HbA1c od izhodišča v primerjavi s placebom, sitagliptinom ali glimepiridom (glejte preglednico 3).
An endpoint called MACE+ (major adverse cardiac events plus) included hospitalisation for unstable angina in addition to the MACE endpoints (acute myocardial infarction, stroke, and CV death). 
Opazovani dogodek, imenovan MACE+ (major adverse cardiac events plus - hujši srčni neželeni učinki plus), je poleg opazovanih dogodkov MACE (akutni miokardni infarkt, možganska kap in kardiovaskularna smrt) obsegal še hospitalizacijo zaradi nestabilne angine pektoris.
2a Hold pen body with clear cartridge pointing up so that you can see the [1] in the window. 
2a Držite telo peresnika tako, da je prozorni vložek obrnjen navzgor in lahko v okencu vidite [1].
In a 52-week monkey study, there was a small increase in pancreas tissue weight at 50 mg/kg/week (75 times clinical exposure based on AUC) associated with acinar cell hypertrophy. 
V 52-tedenski študiji na opicah so ugotovili majhno povečanje mase pankreatičnega tkiva z odmerkom 50 mg/kg/teden (75-kratnik klinične izpostavljenosti na podlagi AUC), povezano s hipertrofijo acinarnih celic.
• allergic reaction (hypersensitivity) ; this includes symptoms such as local or widespread rash, redness or itching of the skin and difficulty breathing (also see ‘Conditions you need to look out for' at the 
• alergijska reakcija (preobčutljivost); to lahko vključuje simptome, kot so lokalni ali razpršen izpuščaj, pordela ali srbeča koža in oteženo dihanje (glejte tudi "Stanja na katera morate biti pozorni"
Albiglutide is an agonist of the GLP-1 receptor and augments glucose-dependent insulin secretion. 
Albiglutid je agonist receptorjev GLP-1 in poveča od glukoze odvisno izločanje insulina.
The hazard ratio for Eperzan versus comparators for MACE+ was 1.0 (95% CI 0.68, 1.49). 
Razmerje ogroženosti za MACE+ je bilo z zdravilom Eperzan v primerjavi s primerjalnimi zdravili 1,0 (95 % IZ: 0,68, 1,49).
A total of 2,365 patients with type 2 diabetes were treated with Eperzan and 2,530 received other study medications in 8 active and placebo-controlled phase III clinical trials. 
Eperzan dobivalo skupaj 2.365 bolnikov s sladkorno boleznijo tipa 2, 2.530 pa jih je dobivalo druga raziskovana zdravila.
If a dose is missed, it should be administered as soon as possible within 3 days after the missed dose. 
V primeru izpuščenega odmerka je treba odmerek uporabiti čim prej v 3 dneh po izpuščenem odmerku.
The Instructions for Use included in the Package Leaflet provide directions for the patient to wait 15 minutes for the 30 mg pen and 30 minutes for the 50 mg pen after the lyophilised powder and diluent are mixed to ensure reconstitution. 
Navodila za uporabo v navodilu za uporabo tega zdravila navajajo, da mora bolnik po premešanju liofiliziranega praška in vehikla počakati 15 minut za 30-mg peresnik in 30 minut za 50-mg peresnik, da je rekonstitucija zagotovljena.
The table presents the adverse reactions that occurred more frequently among patients treated with Eperzan than patients treated with all comparators. 
Preglednica prikazuje neželene učinke, ki so se med prejemniki zdravila Eperzan pojavili pogosteje kot med prejemniki vseh primerjalnih zdravil.
For solids, gastric emptying t1/2 increased from 1.14 h to 2.23 h (p=0.0112). 
Za trdne snovi se je t1/2 praznjenja želodca podaljšal z 1,14 ure na 2,23 ure (p = 0,0112).
This mixes the diluent in the rear chamber of the cartridge with the lyophilised powder in the front chamber. 
To premeša vehikel v zadnjem razdelku vložka z liofiliziranim praškom v sprednjem razdelku.
As albiglutide is a recombinant protein, no genotoxicity studies have been conducted. 
Albiglutid je rekombinantna beljakovina, zato študij genotoksičnosti niso izvedli.
In the Phase III studies in type 2 diabetes patients, small increases in heart rate (1 to 2 bpm) were observed with albiglutide. 
V študijah III. faze pri bolnikih s sladkorno boleznijo tipa 2 so med uporabo albiglutida opažali majhen porast srčne frekvence (1 do 2 utripa na minuto).
The most frequent adverse reactions during clinical trials which occurred in 5% of patients receiving Eperzan were diarrhoea, nausea, and injection site reactions including rash, erythema, or itching at the injection site. 
Najpogostejši neželeni učinki v kliničnih preskušanjih, zabeleženi pri ≥ 5 % bolnikov, ki so prejemali zdravilo Eperzan, so bili driska, naveza in reakcije na mestu injiciranja, vključno z izpuščajem, rdečino ali srbenjem na mestu injiciranja.
No effects were seen at 5 mg/kg/day (at exposures similar to clinical exposure). 
Ob odmerku 5 mg/kg/dan (izpostavljenosti, podobne kliničnim izpostavljenostim) niso opazili učinkov.
The starting total daily dose of insulin glargine ranged between 2 and 40 units (median daily dose of 10 units) and ranged between 3 and 230 units (median daily dose of 30 units) at Week 52. 
Začetni celotni dnevni odmerek insulina glargina je segal od 2 do 40 enot (mediani dnevni odmerek 10 enot), 52. teden pa od 3 do 230 enot (mediani dnevni odmerek 30 enot).
ITTa (N) 
ZNZa (N)
DO NOT shake the pen to avoid foaming, which may affect your dose. 
NE STRESAJTE peresnika, da se ne pojavi pena, ki lahko neugodno vpliva na vaš odmerek .
If you have questions or do not understand how to use your pen, talk to your doctor, nurse or pharmacist. 
Če imate vprašanja, ali če ne razumete, kako uporabiti peresnik, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
• DO NOT reuse needles, recap needles, or remove used needles from the pen. 
• Igel peresnika NE UPORABITE ZNOVA, ne nameščajte nanje snetega pokrovčka ter uporabljenih igel ne odstranjujte s peresnika.
Albiglutide showed no impact on the safety of simvastatin in clinical studies. 
Albiglutid v kliničnih študijah ni vplival na varnost simvastatina.
If you do not push the needle on completely, the pen may jam or leak. 
Če igle ne potisnete do konca na peresnik, se peresnik lahko zatakne ali pušča.
Set a timer for 15 minutes. 
Nastavite štoparico na 15 minut.
Get medical help immediately if you get these symptoms. 
Če dobite te simptome, nemudoma poiščite zdravniško pomoč.
Table 8. 
IN 8.
Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: Monotherapy 
Zdravilo Eperzan je indicirano za zdravljenje sladkorne bolezni tipa 2 pri odraslih za izboljšanje urejenosti glikemije kot:
Reductions in oestrous cycles were observed at 50 mg/kg/day, a dose associated with maternal toxicity (body weight loss and reduced food consumption). 
Pri 50 mg/kg/dan so opazili zmanjšanje estrusnih ciklusov; ta odmerek je bil povezan s toksičnostjo za samice-matere (izguba telesne mase in manjše uživanje hrane).
When Eperzan was used as monotherapy, the incidence of symptomatic hypoglycaemia (<3.9 mmol/l) was similar for Eperzan 30 mg (2%), Eperzan 50 mg (1%) and placebo (3%). 
Med monoterapijo z zdravilom Eperzan je bila incidenca simptomatskih hipoglikemij (< 3,9 mmol/l) z zdravilom Eperzan 30 mg (2 %), Eperzan 50 mg (1 %) in placebom (3 %) podobna.
After I give my medicine, there is some liquid still seen in the clear cartridge. 
Potem ko si injiciram zdravilo, v prozornem vložku še vedno ostane nekaj tekočine.
There is no experience in patients with NYHA class III-IV cardiac failure. 
Izkušenj pri bolnikih s srčnim popuščanjem v razredih III in IV po NYHA ni.
Change at Week 52b 
Sprememba po 52 tednihb
9b Immediately put the pen (with needle attached) in a container for pen disposal. 
9b Peresnik (z nameščeno iglo) takoj dajte v vsebnik za odlaganje peresnika.
Populations not studied 
Neraziskane populacije
ITT a (N) 
ZNZ a (N)
After you have used the pen, do not remove the needle. 
Po uporabi peresnika ne odstranite igle.
In patients with type 2 diabetes who received 2 doses of albiglutide 32 mg (Day 1 and 8), a statistically significant reduction (24%) in postprandial glucose AUC(0.5-4.5 h) was observed compared to placebo following a standardised breakfast meal on Day 9. 
Pri bolnikih s sladkorno boleznijo tipa 2, ki so prejeli 2 odmerka 32 mg albiglutida (1. in 8. dan), so po standardiziranem zajtrku 9. dan opažali statistično značilno znižanje (24 %) postprandialne AUC(0,5-4,5 ure)
Acarbose is contraindicated in patients with intestinal obstruction. 
Akarboza je kontraindicirana pri bolnikih z zaporo črevesa.
The change from baseline in weight for Eperzan did not differ significantly from placebo but was significantly less compared to pioglitazone (see Table 5). 
Sprememba telesne mase v primerjavi z izhodiščem se z zdravilom Eperzan ni značilno razlikovala od placeba, bila pa je značilno manjša kot s pioglitazonom (glejte preglednico 5).